title: The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
abstract: Metastatic prostate cancer is one of the leading causes of cancer death in men. Although initially responsive to hormone therapy, it eventually progresses in almost all patients. For this reason, there has been a search for novel agents to use in the fight against androgen-independent prostate cancer. Antiangiogenesis is a relatively new antitumor strategy that has been employed in the treatments of many malignancies. As prostate cancer is likely dependent on angiogenesis for its growth and progression, it would logically serve as a good target for this modality. Initially met with great enthusiasm, antiangiogenic drugs have seen only limited success when used as single agents. This has been attributed to many possible etiologies including lack of cytotoxicity and use in situations of large tumor burden. In order to overcome these problems, many investigators are combining antiangiogenic agents with more traditional cytotoxic chemotherapy regimens in hope of augmenting the effects of either drug alone. This article will review the background of angiogenesis inhibition and the use of such combinations in metastatic prostate cancer.
authors.affiliation: Center for Cancer Research, National Cancer Institute/NIH, 10 Center Drive, 12N226, Bethesda, MD 20892, USA.
authors.forename: Avi S
authors.initials: AS
authors.lastname: Retter
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
authors.forename: William L
authors.initials: WL
authors.lastname: Dahut
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D003510:Cyclohexanes; D006801:Humans; D008297:Male; D008911:Minocycline / Q000008:administration & dosage; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000503:physiopathology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D017239:Paclitaxel / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D012717:Sesquiterpenes / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000068258:Bevacizumab; D008911:Minocycline; D017239:Paclitaxel; D000077609:O-(Chloroacetylcarbamoyl)fumagillol